期刊文献+

Peg-IFNα 2b联合伊马替尼对耐伊马替尼胃肠间质瘤细胞株的抑制作用 被引量:1

Inhibitory effects of Peg-IFNα 2b and imatinib,alone or in combination,on imatinibresistant gastrointestinal stromal tumor cell line PC9/GR
下载PDF
导出
摘要 目的:探讨聚乙二醇(polyethylene glycol,Peg)修饰重组人干扰素α2b[Peg-(interferonα,I F Nα)2b]联合伊马替尼对耐伊马替尼胃肠道间质瘤(gastrointestinal stromal tumors,GISTs)细胞株的增殖和凋亡的影响及其可能机制.方法:培养C-kit二次突变所致继发性耐药的G I S Ts患者的原代细胞株G I S T-R和对伊马替尼敏感GIST-T1细胞株模拟临床胃肠间质瘤获得性耐药过程;Peg-IFNα2b和伊马替尼单独或联合组处理细胞;MTT法检测细胞的增殖并计算耐药指数、联合指数,FCM法检测细胞凋亡率,Western blot检测p-mT OR和Bcl-2蛋白表达水平.结果:GIST-R细胞株对伊马替尼高度耐药,其耐药指数(RI=46.14),Peg-IFNα2b单独用药对GISTs细胞株均无明显增殖抑制作用;I N F-α与伊马替尼联合用药组对G I S T-R抑制率明显高于伊马替尼单独用药,耐药指数下降(RI=14.79),表现明显的协同增敏效应(CI=0.79).FCM检测结果表明,Peg-IFNα2b与伊马替尼联合用药具有明显的促细胞凋亡的作用.与单药组比较,Peg-IFNα2b与伊马替尼联合用药可明显下调耐伊马替尼细胞p-m TOR和Bcl-2蛋白表达水平(P<0.01).结论:Peg-IFNα2b可以提高GISTs耐药细胞株细胞对伊马替尼的敏感性,这一协同增敏效应可能与下调p-m TOR蛋白表达水平以及诱导细胞凋亡有关. AIM: To investigate the inhibition effects of polyethylene glycol interferon α 2b (Peg-IFNα 2b) and imatinib, alone or in combination, on imatinib-resistant gastrointestinal stromal tumor (GIST) cell line (GIST-R), and to explore the possible mechanism. IFNα 2b and imatinib, alone or in combination. The rate of reduced proliferation and the combination index (CI) in different treatment groups were detected by MTT assay. The apoptotic rate was detected by flow cytometry. The expression of phosphorylated mammalian target of rapamycin (p-mTOR) and Bcl-2 was analyzed by Western blot. RESULTS: GIST-R cells presented remarkable resistance to imatinib, and the resistance index (RI) was 46.14. The rate of reduced proliferation in the combination group was significantly higher than those in the Peg-IFNα 2b or imatinib alone groups (P 〈 0.05). The calculated CI values in the combination group suggested a synergistic effect. Compared with non-treated GIST-R cells, the expression levels of p-roTOR and Bcl-2 proteins in GIST-R cells treated with Peg-IFNα 2b and imatinib significantly decreased (P 〈 0.01). CONCLUSION: The combination of Peg-IFNα 2b and imatinib generates a synergistic effect in GIST-R cells. This effect may be related with apoptosis and the down-regulation of the expression of p-roTOR.
出处 《世界华人消化杂志》 CAS 2015年第1期85-92,共8页 World Chinese Journal of Digestology
基金 湖南省科技厅基金资助项目 No.2013FJ4078~~
关键词 胃肠间质瘤 耐药 聚乙二醇-干扰素α2b 伊马替尼 联合 增敏 GIST Drug resistance Polyethyleneglycol interferon α2b Imatinib Combination Sen-sibilization
  • 相关文献

参考文献19

  • 1Agaimy A, Wtinsch PH, Hofstaedter F, Blaszyk H, Rflmmele P, Gaumann A, Dietmaier W, Hartmann A. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007; 31:113-120 [PMID: 17197927 DOI: 10.1097/01. pas.0000213307.05811.f0].
  • 2Heinrich MC, Corless CL, Demetri GD, Blanke CD, yon Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21:4342-4349 [PMID: 14645423 DOI: 10.1200/JCO.2003.04.190].
  • 3Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, Leversha MA, Jeffrey PD, Desantis D, Singer S, Brennan MF, Maki RG, DeMatteo RP. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005; 11:4182-4190 [PMID: 15930355 DOI: 10.1158/1078-0432.CCR- 04-2245].
  • 4McLean SR, Gana-Weisz M, Hartzoulakis B, Frow R, Whelan J, Selwood D, Boshoff C. Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Va1654Ala. Mol Cancer Ther 2005; 4:2008-2015 [PMID: 16373716 DOI: l O.1158 /1535- 7163.M CT-05-O070 ].
  • 5Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinalstromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626-632 [PMID: 18235122 DOh 10.1200/JCO.2007.13.4452].
  • 6Zalcberg JR, Verweii J, Casali PG, Le Cesne A, Reichardt P, Blay JY, Schlemmer M, Van Glabbeke M, Brown M, Judson IR. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41:1751-1757 [PMID: 16098458 DOI: 10.1016/ j.ejca.2005.04.034].
  • 7Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM, Mendel DB. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SUl1248. Mol Cancer Ther 2006; 5: 1280-1289 [PMID: 16731761 DOI: 10.1158/1535-7163. MCT-03-0156].
  • 8Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY, Bokemeyer C, Deininger MW, Druker BJ, Heinrich MC. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66:473-481 [PMID: 16397263 DOI: 10.1158/0008-5472.CAN-05-2050].
  • 9Braconi C, Bracci R, Cellerino R. Molecular targets in Gastrointestinal Stromal Tumors (GIST) therapy. Curr Cancer Drug Targets 2008; 8:359-366 [PMID: 18690842 DOI: 10.2174/156800908785133169].
  • 10Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002; 8:2255-2257 [PMID: 12369853 DOI: 10.2174/1381612023393026].

同被引文献10

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部